Introduction The clinical syndrome of Parkinsonism is most frequently caused by Parkinson’s disease (PD). These two conditions share many symptoms, and, as a result, the proposed treatment methods are similar in both illnesses. Since the cases of Parkinsonism symptoms development as a result of using some medications are numerous, scientists are constantly working on the improvement of the techniques employed in the treatment of Parkinsonism and Parkinson’s disease. Numerous experiments are being performed to check the validity of drugs proposed to relieve the symptoms of the two conditions. Future management modalities involve clinical trials, new medicines, and original therapeutic approaches. Experimental and Future Clinical Options for PD Treatment The most common pharmacotherapy options for PD treatment are L -DOPA, monoamine oxidase, amantadine, and dopamine agonists. However, with the disease’s progress, these options become insufficient, and their side effects begin to show. To improve the existing treatment methods, researchers are constantly working on finding out new drugs and clinical modalities that would decrease the progress of Parkinsonism and PD. While the application of creatine monohydrate, coenzyme Q10, pioglitazone, and other drugs has not brought positive results, current clinical trials are aimed at investigating the outcomes of the application of other medicine. Among the new options are isradipine, nicotine, inosine, caffeine, and immunization against α-synuclein. 1 Other treatment options incorporate gene therapy and treatment addressing non-dopaminergic systems. 2 Adenosine A 2A Antagonists as a Promising Drug Category Since neurotransmitters are partially responsible for Parkinson’s disease’s symptomatology, perspectives of future research include the development of non-dopaminergic PD therapies. Out of all the current drug categories, researchers consider adenosine A 2A antagonists as a highly prospective solution. 3 Adenosine A 2A antagonists’ positive anti-parkinsonian reaction has allowed proposing a rationale for clinical trials which will assess the safety and therapeutic capacity of these antagonists in the PD patients. Modern pharmacological attempts connected with the potential application of A 2A antagonists in PD therapy are concentrated on examination of vipadenant and preladenant, modern derivatives in drugs’ development such as SYN115, and a comparatively old drug istradefylline which has recently been approved in Japan as an anti-parkinsonian drug. 3 The benefits of the A 2A receptor blockade have been proven in several experimental models. Experiments demonstrated that a combined treatment by A 2A antagonist and L -DOPA eliminated the wearing-off generated by L -DOPA without declining dyskinesia. Additionally, a low L -DOPA dose led to motor symptoms improvement with less dyskinesia. 3 Despite their positive impact on the disease, adenosine A 2A antagonists may present some side effects on the patients. These effects include lowered blood pressure, vomiting, and nausea. The application of the drug for a long time may cause a decrease in its efficiency and disease advancement. Preladenant Experimental application of preladenant showed a mean reduction in OFF time and an insignificant increase in ON time. The future study involv